349 related articles for article (PubMed ID: 11695556)
21. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
22. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
Tamaoki N
Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
[TBL] [Abstract][Full Text] [Related]
23. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.
Wells MY; Williams ES
Regul Toxicol Pharmacol; 2009 Mar; 53(2):150-5. PubMed ID: 19126422
[TBL] [Abstract][Full Text] [Related]
24. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
[TBL] [Abstract][Full Text] [Related]
25. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
Robinson DE; MacDonald JS
Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
[TBL] [Abstract][Full Text] [Related]
26. The syrian hamster embryo (SHE) cell transformation assay: review of the methods and results.
Mauthe RJ; Gibson DP; Bunch RT; Custer L
Toxicol Pathol; 2001; 29 Suppl():138-46. PubMed ID: 11695550
[TBL] [Abstract][Full Text] [Related]
27. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
[TBL] [Abstract][Full Text] [Related]
28. Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa-/-p53+/- mice upon exposure to benzo[a]pyrene.
van Kesteren PC; Zwart PE; Pennings JL; Gottschalk WH; Kleinjans JC; van Delft JH; van Steeg H; Luijten M
Toxicol Sci; 2011 Sep; 123(1):123-32. PubMed ID: 21715664
[TBL] [Abstract][Full Text] [Related]
29. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.
Tennant RW; Stasiewicz S; Eastin WC; Mennear JH; Spalding JW
Toxicol Pathol; 2001; 29 Suppl():51-9. PubMed ID: 11695562
[TBL] [Abstract][Full Text] [Related]
30. The role of transgenic mouse models in carcinogen identification.
Pritchard JB; French JE; Davis BJ; Haseman JK
Environ Health Perspect; 2003 Apr; 111(4):444-54. PubMed ID: 12676597
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens.
Tennant RW; Spalding J; French JE
Mutat Res; 1996 Sep; 365(1-3):119-27. PubMed ID: 8898993
[TBL] [Abstract][Full Text] [Related]
32. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
33. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
34. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
[TBL] [Abstract][Full Text] [Related]
35. Alternatives to the carcinogenicity bioassay for toxicity prediction: are we there yet?
Benigni R
Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):407-17. PubMed ID: 22360376
[TBL] [Abstract][Full Text] [Related]
36. Criteria for the evaluation of studies in transgenic models.
Popp JA
Toxicol Pathol; 2001; 29 Suppl():20-3. PubMed ID: 11695558
[TBL] [Abstract][Full Text] [Related]
37. Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models.
Jonker MJ; Bruning O; van Iterson M; Schaap MM; van der Hoeven TV; Vrieling H; Beems RB; de Vries A; van Steeg H; Breit TM; Luijten M
Carcinogenesis; 2009 Oct; 30(10):1805-12. PubMed ID: 19696161
[TBL] [Abstract][Full Text] [Related]
38. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
39. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice.
Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W
Toxicol Pathol; 1998; 26(4):501-11. PubMed ID: 9715509
[TBL] [Abstract][Full Text] [Related]
40. Application of genetically altered models as replacement for the lifetime mouse bioassay in pharmaceutical development.
Alden C; Smith P; Morton D
Toxicol Pathol; 2002; 30(1):135-8. PubMed ID: 11890466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
